Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 2005年6月，自然人周晶晶、林长青、魏红山、杨晓兰以非专利技术，共同出资设立北京热景生物技术有限公司，公司注册资本为50万元。 公司系由北京热景生物技术有限公司整体变更设立，并于2016年5月27日取得了统-社会信用代码为9111777090586H号的营业执照，注册资本为4,365万元。热景有限由周晶晶、林长青、魏红山和杨晓兰共同出资组建，并于2005年6月23日在北京市工商行政管理局海淀分局注册成立,注册资本50万元。首次出资业经华青会计师事务所有限公司华青验字(2005)第w347号《验资报告》验证。 北京热景生物技术股份有限公司是一家从事研发、生产和销售体外诊断仪器和试剂的生物高新技术企业,以“发展生物科技,造福人类健康”为使命,秉承“检验因我而先进”的理念,持续聚焦医学与公共安全检测领域产品的创新与产业化。热景生物的主要产品为体外诊断试剂及配套仪器,主要应用于肝癌肝炎、心脑血管疾病、炎症感染等临床领域和生物反恐、食品安全、疾控应急等公共安全领域。热景生物经过持续多年技术研发,构建了以上转发光技术、磁微粒化学发光技术、糖捕获技术、基因重组与单克隆抗体技术为核心的研发技术平台,开发了一系列的体外诊断试剂及仪器,可应用于全场景的免疫诊断。其中上转发光技术率先将稀土元素所构成的上转发光材料(UCP)应用于临床及生物安全领域,并荣获2015年国家技术发明二等奖。磁微粒化学发光作为免疫诊断的国际主流先进技术,热景生物通过持续多年研发投入,掌握了单人份化学发光和高通量化学发光技术,连续开发出小型、中型、大型全自动化学发光仪器和试剂产品,构建起可满足不同终端用户需求的全场景(POCT现场快速检测、中心实验室自动化高通量检测)发光诊断平台,成为业内为数不多的产品涵盖全场景应用的供应商之一。热景生物丰富的产品线能够充分满足各类客户在不同设备条件或成本要求下的诊断或检测需求。
Main Business 紧紧围绕创新生物技术，布局从疾病的早期筛查、诊断到治疗的解决方案。
Legal Representative 林长青
Top Executives
董事长：林长青
董事：石永沾,李艳召,柳晓利
独立董事：宋云锋,喻长远,徐小舸
Top 5 Shareholder
Shareholder name Nature Holding Date
林长青流通A股23.45%30/09/2024
周锌流通A股7.36%30/09/2024
青岛同程热景企业管理咨询合伙企业（有限合伙）流通A股4.55%30/09/2024
北京热景生物技术股份有限公司回购专用证券账户流通A股3.13%30/09/2024
北京热景生物技术股份有限公司－2024年员工持股计划流通A股3.09%30/09/2024
Company Secretary 石永沾
Solicitors 北京市康达律师事务所
Auditors 华普天健会计师事务所（特殊普通合伙）
Tel No 010-50986527
Fax No 010-56528861
Website www.hotgen.com.cn
Email hotgen@hotgen.com.cn
Company Address
Register: 北京市大兴区中关村科技园区大兴生物医药产业基地庆丰西路55号院7号楼1-5层
Office: 北京市大兴区中关村科技园区大兴生物医药产业基地庆丰西路55号院7号楼1-5层
Listing Date 30/09/2019
Shares Capital
Shares Capital: 92,474,692
Total A Share: 92,474,692
Listed A Share: 92,474,692
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.310
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 36.415
Market Capitalization(RMB) 2.845B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.